ScholarIQanswers from OpenAlex & ORCID
Gwo Fuang Ho
ResearcherPublications, citations & collaboration network
Gwo Fuang Ho is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Gwo Fuang Ho have?
ScholarIQindexed works
Gwo Fuang Ho has 161 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Gwo Fuang Ho have?
ScholarIQcitation count
Gwo Fuang Ho has 3,027 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Gwo Fuang Ho?
ScholarIQh-index
Gwo Fuang Ho has an h-index of 28 in OpenAlex.
What is the i10-index of Gwo Fuang Ho?
ScholarIQi10-index
Gwo Fuang Ho has an i10-index of 62 in OpenAlex.
What is the ORCID of Gwo Fuang Ho?
ScholarIQorcid
The ORCID for Gwo Fuang Ho is on the source record.
What is the OpenAlex record for Gwo Fuang Ho?
ScholarIQopenalex
The OpenAlex for Gwo Fuang Ho is on the source record.
What are the most-cited papers on Gwo Fuang Ho?
ScholarIQmost cited works
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
L.-T. Chen, Erika Martinelli, Ann‐Lii Cheng, George Pentheroudakis, Si-bei Qin, G.S. Bhattacharyya, Masafumi Ikeda, Ho Yeong Lim, Gwo Fuang Ho, Su Pin Choo, Zhenggang Ren, Hemant Malhotra, Makoto Ueno, Baek‐Yeol Ryoo, Tina Kiang, David Tai, Arndt Vogel, Andrés Cervantes, Sheng‐Nan Lu, Chung‐Jen Yen, Yi‐Hsiang Huang, San‐Chi Chen, Chiun Hsu, Ying‐Chun Shen, Josep Tabernero, Yun Yen, Chih‐Hung Hsu, Takayuki Yoshino, J.-Y. Douillard
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial
Shukui Qin, Zhendong Chen, Weijia Fang, Zhenggang Ren, Ruocai Xu, Baek‐Yeol Ryoo, Zhiqiang Meng, Yuxian Bai, Xiaoming Chen, Xiufeng Liu, Juxiang Xiao, Gwo Fuang Ho, Yimin Mao, Xin Wang, Jieer Ying, Jianfeng Li, Wenyan Zhong, Yu Zhou, Abby B. Siegel, Chunyi Hao
Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non‐small cell lung cancer or colorectal cancer: a randomized, double‐blind, placebo‐controlled, international multicentre phase II study (the ACT‐ONE trial)
Andrew J.S. Coats, Gwo Fuang Ho, Kumar Prabhash, Stephan von Haehling, Julia Tilson, R. H. Brown, John Beadle, Stefan D. Anker, for and on behalf of the ACT‐ONE study group
Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline
Ainhoa Costas‐Chavarri, Govind Nandakumar, Sarah Temin, Gilberto Lopes, Andrés Cervantes, Marcia Cruz Correa, R. Engineer, Chisato Hamashima, Gwo Fuang Ho, Fidel David Huitzil, Mona Malekzadeh, Ala I. Sharara, Mariana C. Stern, Catherine Teh, Sara E. Vázquez Manjarrez, Azmina Verjee, Rhonda K. Yantiss, Manish A. Shah
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
Anthony T.�C. Chan, V.H.F. Lee, R-L. Hong, M-J. Ahn, Wan Qin Chong, S. B. Kim, Gwo Fuang Ho, Priscilla B. Caguioa, Nuttapong Ngamphaiboon, Cheryl Ho, Mubashir Aziz, Quan Sing Ng, C-J. Yen, Nopadol Soparattanapaisarn, Roger KC Ngan, S.K. Kho, M.L.A. Tiambeng, Tak Yun, Virote Sriuranpong, Alain P. Algazi, Andy S. K. Cheng, Erminia Massarelli, Ramona F. Swaby, Sanatan Saraf, Jianda Yuan, Lillian L. Siu